Dr. Ravi Salgia Describes Molecular Applications In Advanced Lung Cancer

Dr. Ravi Salgia Describes Molecular Applications in Advanced Lung Cancer

Targeted Oncology

ASCO22 Lung Cancer Key Takeaways | Ravi Salgia, MD, PhD | 2022 Review and Renew Sedona

Total Health | Oncology

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

GRACEcastUC098_Lung_Dr. Salgia on CollabRx Matching Mutations to Clinical Trials

GRACE - Global Resource for Advancing Cancer Education

Dr. Salgia on Importance of Molecular Markers in Lung Cancer

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

Meet Medical Oncologist and Chair Ravi Salgia, M.D., Ph.D. | City of Hope

Ravi Salgia, MD, PhD | What's Exciting About Lung Cancer at 2018 Best of ASCO St. Louis

Total Health | Oncology

ASCO Lung Cancer Update | Ravi Salgia, MD, PhD | 2022 Review and Renew Sedona

Total Health | Oncology

Dr. Ravi Salgia on EML4-ALK in a Cancer Cell

Targeted Oncology

Dr. Ravi Salgia on Crizotinib-Resistant Patients

Targeted Oncology

Dr. Salgia on Next-Generation Sequencing in Lung Cancer

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

GRACEcastUC108_Lung_Dr. Salgia on Targeted Therapies Generalizable

GRACE - Global Resource for Advancing Cancer Education

GRACEcastUC081_Lung_Which Patients Send For Molecular Testing

GRACE - Global Resource for Advancing Cancer Education

Every Patient Counts, Every Story Matters: Jeff and Dr. Ravi Salgia

Benefits of targeted therapeutics in Lung Cancer

2021 ASCO Direct San Francisco | Metastatic Lung Cancer Summary | Dr. Ravi Salgia

Total Health | Oncology

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

GRACEcastUC-059_Lung_Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"

GRACE - Global Resource for Advancing Cancer Education